Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.68 |
| ▸ | DRD2 | P14416 | 3/20 | 0.59 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6589336 | 0.90 | DRD2 (0.59) | HTR1ASLC6A4DRD2HTR7HTR6 | |
| SCHEMBL6591284 | 0.84 | DRD2 (0.59) | HTR1ASLC6A4DRD2 | |
| SCHEMBL6610951 | 0.83 | HTR1A (0.64) | HTR1ASLC6A4 | |
| SCHEMBL7533659 | 0.83 | HTR1A (0.62) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL7220964 | 0.81 | HTR1A (1.00) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| SCHEMBL6588929 | 0.81 | HTR1A (0.60) | HTR1ASLC6A4DRD2DRD4HTR2A | |
| Oxalic Acid SCHEMBL6773377 | 0.80 | DRD2 (0.54) | HTR1ASLC6A4DRD2 | |
| SCHEMBL6591394 | 0.79 | DRD2 (0.89) | HTR1ADRD2HTR7 | |
| SCHEMBL6586953 | 0.78 | DRD2 (0.64) | HTR1ASLC6A4DRD2HTR7HTR6 | |
| SCHEMBL8554164 | 0.77 | DRD2 (0.69) | HTR1ASLC6A4DRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007523-B9 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-09-08 | — | — | EP | claimed |
| CN-1515568-A | Indole and 2,3-indoline derivative, their preparation and application | H.隆德贝克有限公司 | 2004-07-28 | — | — | CN | claimed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | claimed |
| EP-1007523-B1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | claimed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | claimed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | claimed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | HTR1A 2/4885SLC6A4 25/4885DRD2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.